drugset / Trial / NCT00895947

Interferon Alpha Lozenges in the Prevention of Winter Colds and Flu

NCT00895947

RandomizedParallel-groupQuadruple-blindPrevention

Summary

The aim of the study is to see if lozenges containing a low dose of interferon-alpha can prevent and/or reduce the severity of colds and flu. Starting about 1 month before the expected start of the winter colds and flu season in Perth, Australia, healthy volunteers will allow a lozenge containing interferon, or a lozenge containing no medicine (a placebo), to dissolve in their mouth once a day for 16 weeks. Blood tests at the start and end of treatment will determine whether interferon was able to prevent infections with cold/flu viruses. Once a week, volunteers will complete a survey about their cold/flu symptoms, medications taken, days of work missed, etc. to see if interferon was able to make their winter colds and flu less severe.

Timeline

Start
2009-04
Primary completion
2010-01
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject interferon alfa-2b Protein / enzyme biologic 150 iu Oral